Experimental chikungunya vaccine induces strong antibody response

08/14/2014 | Reuters · Bloomberg Businessweek

A clinical trial involving 25 healthy volunteers found that an experimental chikungunya vaccine developed by U.S. government researchers triggered a strong immune response against the mosquito-borne viral disease. Different doses were tested over the course of three injections, and antibodies to chikungunya were still present at least 11 months after the last dose, according to findings reported in The Lancet.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC